Table 2.
Siglec-targeted antibodies in clinical development for treatment of immune cell diseases
Antibody | Target | Construct | Status |
---|---|---|---|
Gemtuzumab ozogamicin (Mylotarg™) |
CD33 | Humanized murine IgG conjugated to calicheamicin |
Approved for AML |
CMC-544 | CD22 | IgG4 conjugated to calecheamicin |
Phase II/III for NHL |
BL22 | CD22 | Recombinant Ig- pseudomonas toxin conjugate |
Phase II for hairy cell leukemia |
Epratuzumab | CD22 | Humanized IgG1 | Phase III |